Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis

JE Miller, MZ Molnar, CP Kovesdy… - … and drug safety, 2012 - Wiley Online Library
Purpose Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …
被引用次数：32 相关文章
[PDF] researchgate.net

[PDF][PDF] Administered Paricalcitol Dose and Survival in Hemodialysis Patients: A Marginal Structural Model Analysis

Pharmacoepidemiol Drug Saf, 2012 - researchgate.net
Purpose—Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis.

JE Miller, MZ Molnar, CP Kovesdy… - … and Drug Safety, 2012 - europepmc.org
Purpose Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …

Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis

JE Miller, MZ Molnar, CP Kovesdy… - … and Drug Safety, 2012 - escholarship.org
PurposeSeveral observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …

Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis

JE Miller, MZ Molnar, CP Kovesdy, JJ Zaritsky… - … and Drug Safety, 2012 - cir.nii.ac.jp
抄録< jats: title> ABSTRACT</jats: title>< jats: sec>< jats: title> Purpose</jats: title>< jats: p>
Several observational studies have indicated that vitamin D receptor activators (VDRA) …

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis

JE Miller, MZ Molnar, CP Kovesdy… - … and drug safety, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …

Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis

JE Miller, MZ Molnar, CP Kovesdy, JJ Zaritsky… - … and Drug Safety, 2012 - infona.pl
Purpose Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …
[HTML] nih.gov

[HTML][HTML] Administered Paricalcitol Dose and Survival in Hemodialysis Patients: A Marginal Structural Model Analysis

JE Miller, MZ Molnar, CP Kovesdy… - … and drug safety, 2012 - ncbi.nlm.nih.gov
Purpose Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis.

JE Miller, MZ Molnar, CP Kovesdy… - … and Drug Safety, 2012 - europepmc.org
Purpose Several observational studies have indicated that vitamin D receptor activators
(VDRA), including paricalcitol, are associated with greater survival in maintenance …